Tiotropium bromide is a long-acting, anticholinergic bronchodilator (antimuscarinic agent) used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It acts as a competitive antagonist at M1, M2, and M3 muscarinic receptors in the lungs, with kinetic selectivity for M1 and M3 receptors, leading to sustained bronchodilation. The 9mcg dose is delivered via a dry powder inhaler (DPI) device, providing a once-daily dosing regimen that improves lung function, reduces dyspnea, and decreases exacerbation frequency.
Adult: 9 mcg once daily via the specific dry powder inhaler device.
Note: For use with a specific DPI device (e.g., HandiHaler, Breezhaler, or other generic device). Instructions: 1) Open the device/capsule blister. 2) Place the 9mcg capsule in the chamber of the device. 3) Close the device until a click is heard, piercing the capsule. 4) Exhale fully away from the device. 5) Place mouthpiece between lips and inhale deeply and forcefully. 6) Hold breath for 10 seconds. 7) Repeat inhalation from the same capsule to ensure full dose. 8) Discard the empty capsule. Rinse mouth with water after inhalation to reduce dry mouth and potential oropharyngeal candidiasis.
Tiotropium is a competitive, reversible antagonist of muscarinic (M3) receptors on airway smooth muscle and submucosal glands. By blocking acetylcholine binding, it inhibits bronchoconstriction and mucus secretion mediated by the parasympathetic nervous system.
Pregnancy: Category C: Animal studies have shown evidence of fetal toxicity (reduced fetal weight, delayed ossification) at high doses. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus. Inhaled route minimizes systemic exposure.
Driving: May cause blurred vision or dizziness in some patients. Patients should be cautioned about operating machinery or driving until they are certain tiotropium does not affect them adversely.
| Other Anticholinergic Drugs (e.g., Ipratropium, Aclidinium, Glycopyrrolate, Atropine, Tricyclic Antidepressants, Antihistamines) | Additive anticholinergic side effects (dry mouth, constipation, urinary retention, blurred vision, tachycardia). | Moderate |
| Beta-adrenergic Agonists (e.g., Salbutamol, Formoterol, Salmeterol) | Additive bronchodilator effect; commonly used together in COPD management. Monitor for tachycardia and hypokalemia. | Mild |
| Potassium-wasting Diuretics (e.g., Furosemide, Hydrochlorothiazide) + Beta-agonists | Increased risk of hypokalemia and ECG changes. Monitor potassium levels. | Moderate |
| Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) | Potentiation of anticholinergic effects. | Moderate |